Papantoniou Konstantinos, Kafentzi Theodora, Sotiropoulos Christos, Thomopoulos Konstantinos C, Konstantakis Christos
Department of Internal Medicine, Division of Gastroenterology, Patras Medical School, University of Patras, Patras, GRC.
Cureus. 2025 May 6;17(5):e83611. doi: 10.7759/cureus.83611. eCollection 2025 May.
Malignant tumors of the upper gastrointestinal (GI) tract are a common cause of GI bleeding, often presenting therapeutic challenges due to diffuse hemorrhage and poor visualization. Local hemostatic agents, such as TC-325 (Hemospray; Winston-Salem, NC: Cook Medical), have emerged as effective bridging therapies prior to definitive treatment. However, visceral perforation, though rare, is a serious complication associated with TC-325 use. We present a case of an 87-year-old male with metastatic gastric adenocarcinoma who experienced visceral perforation following TC-325 application for recurrent upper GI bleeding. Despite achieving initial hemostasis, the patient succumbed to complications of perforation. This study highlights the need for caution when using TC-325 in patients with advanced malignancies and friable tissue.
上消化道（GI）恶性肿瘤是GI出血的常见原因，由于弥漫性出血和视野不佳，常常带来治疗挑战。局部止血剂，如TC-325（Hemospray；北卡罗来纳州温斯顿 - 塞勒姆：库克医疗公司），已成为确定性治疗前有效的过渡治疗方法。然而，内脏穿孔虽然罕见，但却是与使用TC-325相关的严重并发症。我们报告一例87岁男性转移性胃腺癌患者，在应用TC-325治疗复发性上消化道出血后发生内脏穿孔。尽管最初实现了止血，但患者最终死于穿孔并发症。本研究强调在晚期恶性肿瘤和组织脆弱的患者中使用TC-325时需要谨慎。
